Published in Breast Cancer Res Treat on August 14, 2008
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry. J Clin Oncol (2011) 2.13
Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) (2010) 2.08
A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res (2010) 1.68
Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res (2010) 1.26
Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res (2012) 1.24
Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet (2011) 1.12
Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2012) 1.01
Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry. Cancer Epidemiol Biomarkers Prev (2009) 1.00
Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep (2011) 0.95
Morphological predictors of BRCA1 germline mutations in young women with breast cancer. Br J Cancer (2011) 0.94
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet (2010) 0.94
Collaborative cancer epidemiology in the 21st century: the model of cancer consortia. Cancer Epidemiol Biomarkers Prev (2013) 0.92
Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. Breast Cancer Res Treat (2008) 0.88
Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). Int J Epidemiol (2015) 0.87
Tumour morphology predicts PALB2 germline mutation status. Br J Cancer (2013) 0.85
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer (2016) 0.83
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry. Breast Cancer Res Treat (2015) 0.83
Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2013) 0.81
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. Breast Cancer Res (2011) 0.79
Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Res Treat (2015) 0.78
Racial and ethnic differences in adjuvant hormonal therapy use. J Womens Health (Larchmt) (2012) 0.77
Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry. PLoS One (2016) 0.77
Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry. Br J Cancer (2014) 0.77
The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry. Breast Cancer Res Treat (2015) 0.76
Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy. BMC Med Genet (2016) 0.75
Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry. Breast Cancer Res (2017) 0.75
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol (2002) 6.69
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA (2006) 5.51
Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A (1993) 5.47
A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet (2007) 5.17
Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet (2005) 4.98
Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet (2004) 4.61
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA (2007) 4.33
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet (2004) 2.40
Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci U S A (1998) 2.14
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer (1999) 1.71
Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev (2004) 1.45
Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat (2002) 1.44
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat (2006) 1.19
BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev (2006) 1.07
Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev (2006) 1.02
BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study. Eur J Cancer (2007) 1.01
Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. Breast Cancer Res Treat (2007) 1.00
Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study. Cancer Epidemiol Biomarkers Prev (2004) 0.94
No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years. Cancer Epidemiol Biomarkers Prev (2006) 0.93
Determinants of preferences for genetic counselling in Jewish women. Fam Cancer (2006) 0.91
Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies. J Med Genet (2003) 0.86
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Strong association of de novo copy number mutations with autism. Science (2007) 27.84
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (2008) 14.26
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med (2002) 6.19
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev (2007) 6.00
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med (2008) 5.43
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med (2006) 5.10
Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood (2006) 5.05
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med (2011) 4.47
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA (2007) 4.33
Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension (2003) 4.19
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol (2005) 3.99
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75